List of Exparel drug patents

Exparel is owned by Pacira Pharms Inc.

Exparel contains Bupivacaine.

Exparel has a total of 8 drug patents out of which 0 drug patents have expired.

Exparel was authorised for market use on 28 October, 2011.

Exparel is available in injectable, liposomal;injection dosage forms.

Exparel can be used as method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia, method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia.

The generics of Exparel are possible to be released after 22 January, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033495 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11179336 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11278494 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11426348 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11452691 PACIRA PHARMS INC Compositions of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11357727 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11311486 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

US11304904 PACIRA PHARMS INC Manufacturing of bupivacaine multivesicular liposomes
Jan, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 22, 2024

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia; Method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia

Dosage: INJECTABLE, LIPOSOMAL;INJECTION

How can I launch a generic of EXPAREL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in